The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation

2012 ◽  
Vol 8 (5) ◽  
pp. 591-598 ◽  
Author(s):  
Per Thayssen ◽  
Lisette Jensen ◽  
Jens Lassen ◽  
Hans Tilsted ◽  
Anne Kaltoft ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Prognostic Impact ◽  
Stent Restenosis ◽  
Coronary Stent Implantation ◽  
In Stent Restenosis ◽  
Definite Stent Thrombosis

Is In-Stent Restenosis After a Successful Coronary Stent Implantation Due to Stable Angina Associated With TG/HDL-C Ratio?

Angiology ◽  
2017 ◽  
Vol 68 (9) ◽  
pp. 816-822 ◽  
Author(s):  
Harun Kundi ◽  
Ahmet Korkmaz ◽  
Ahmet Balun ◽  
Hulya Cicekcioglu ◽  
Emrullah Kiziltunc ◽  
...  
Keyword(s):  
Stent Implantation ◽  
Stable Angina ◽  
Large Scale ◽  
Cox Regression ◽  
Coronary Stent ◽  
Cox Regression Analysis ◽  
Stent Restenosis ◽  
Coronary Stent Implantation ◽  
The Impact ◽  
In Stent Restenosis

We examined the impact of the preprocedural triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio on risk of in-stent restenosis (ISR). Patients with typical anginal symptoms and/or positive treadmill or myocardial perfusion scintigraphy test results who underwent successful coronary stent implantation due to stable angina were examined; 1341 patients were enrolled. The hospital files of the patients were used to gather data. Cox regression analysis showed that the TG/HDL-C ratio was independently associated with the presence of ISR ( P < .001). Moreover, diabetes mellitus ( P = .007), smaller stent diameter ( P = .046), and smoking status ( P = .001) were also independently associated with the presence of ISR. Using a cutoff of 3.8, the TG/HDL-C ratio predicted the presence of ISR with a sensitivity of 71% and a specificity of 68%. Also, the highest quartile of TG/HDL-C ratio had the highest rate of ISR ( P < .001). Measuring preprocedural TG/HDL-C ratio, in fasting or nonfasting samples, could be beneficial for the risk assessment of ISR. However, further large-scale prospective studies are required to establish the exact role of this simple, easily calculated, and reproducible parameter in the pathogenesis of ISR.

The-374T/A Variant of the Rage Gene Promoter is Associated with Clinical Restenosis after Coronary Stent Placement

2007 ◽  
Vol 20 (4) ◽  
pp. 771-777 ◽  
Author(s):  
C. Falcone ◽  
E. Emanuele ◽  
M.P. Buzzi ◽  
L. Ballerini ◽  
A. Repetto ◽  
...  
Keyword(s):  
Risk Factors ◽  
Protective Effect ◽  
Stent Implantation ◽  
Gene Promoter ◽  
Coronary Stent ◽  
Cell Surface Receptor ◽  
Stent Restenosis ◽  
Coronary Stent Implantation ◽  
Reduced Risk ◽  
In Stent Restenosis

Upregulation of the receptor for advanced glycation end products (RAGE) may play a crucial role in neointimal formation upon vessel injury. The −374T/A variant of the RAGE gene promoter, which has been associated with an altered expression of the cell-surface receptor, could exert a protective effect toward the development of vascular disease. The aim of this study is to determine the impact of this common genetic variant in the occurrence of clinical in-stent restenosis after coronary stent implantation. The −374T/A polymorphism of the RAGE gene promoter was evaluated by PCR-RFLPs in 267 patients with coronary artery disease who underwent coronary stent implantation and a subsequent coronary angiography 6–9 months later for suspected restenosis. In-stent restenosis was assessed by means of quantitative angiography. Carriers of the-374AA genotype showed a significantly reduced risk of developing restenosis after percutaneous transluminal intervention than non-carriers. To determine whether the protective effect of the homozygous AA genotype toward clinical restenosis was independent of potential confounders, we performed multivariable logistic regression analysis. After allowance for clinical and biochemical risk factors and stent length, the AA genotype remained significantly associated with a reduced prevalence of in-stent restenosis. No relation was evident between the RAGE genotype and established cardiovascular risk factors. In conclusion, the −374AA genotype of the RAGE gene promoter could be associated with a reduced risk of in-stent restenosis after coronary stent implantation.

Sign in / Sign up

Export Citation Format

Share Document